Hirokazu Taniguchi

7PUBLICATIONS
9CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Respiratory diseasesMedical physiology not elsewhere classifiedMechanical engineering not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 02, 2026
Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.

|Sep 05, 2022
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.

Ken Masubuchi, Hisao Imai, Satoshi Wasamoto

|Jun 15, 2022
Tracheobronchitis in patients with diffuse wall thickening: Three case reports.

Hirokazu Taniguchi, Yasuaki Masaki, Takeshi Tsuda

|Jun 14, 2022
Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer.

Ayako Shiono, Hisao Imai, Satoshi Wasamoto

|Mar 14, 2022
Bochdalek hernia with liver herniation.

Mao Kanatani, Hirokazu Taniguchi, Kimiho Kusabiraki

|Nov 15, 2018
Chest tightness is relieved with the use of asthma drugs except bronchodilators.

Hirokazu Taniguchi, Yuko Nakanishi, Takeshi Tsuda

Pageof 2

Frequent Collaborators

2 joint publications

Hisao Imai

2 joint publications

Hiroyuki Minemura

2 joint publications

Yutaka Yamada

2 joint publications

Kyoichi Kaira